PCSK9 and triglyceride-rich lipoprotein metabolism

Journal of Biomedical Research

Volumn 29, Issue 6, 2015, Pages 429-436

  Druce, Irena ^a   Abujrad, Hussein ^a   Ooi, Teik Chye ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Hypercholesterolemia; Hyperlipidemia; Molecular biology

Indexed keywords

APOLIPOPROTEIN B; CHYLOMICRON; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PRO PROTEIN CONVERTASE SUBTILISIN KEXIN 9; SERINE PROTEINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; DIABETES MELLITUS; GLUCOSE METABOLISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INTESTINE CELL; LIPID STORAGE; LIPOPROTEIN METABOLISM; LIPOPROTEIN SECRETION; LIPOPROTEIN SYNTHESIS; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84959163895     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.7555/JBR.29.20150052     Document Type: Review

References (75)

1. Seidah NG, Sadr MS, Chrétien M, et al. Thee multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions[J]. J Bio Chem, 2013, 288(30):21473-21481.
2. Seidah NG, Benjannet S, WIckham L, et al. The secretory proprotein covertase neural Liver regeneration and neuronal differentiation[J]. Proc Natl Acad Sci USA, 2002, 100(3):928-933.
3. Labonte P, Begley S, Gúevin C, et al. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression[J]. Hepatology, 2009, 50(1):17-24.
4. Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia[J]. Nat Genet, 2003, 34(2):154-156.
5. Alborn WE, Cao G, Careskey HE, et al. Serum proprotein convertase subtilisin kexin 9 is correlated directly with serum LDL cholesterol[J]. Clin Chem, 2007, 53(10):1814-1819.
6. Dubuc G, Tremblay M, ParéG, et al. A new method for measurement of total plasma PCSK9: clinical applications[ J]. J Lipid Res, 2010, 51(1):140-149.
7. Lambert G, Ancellin N, Charlton F, et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment[J]. Clin Chem, 2008, 54(6):1038-1045.
8. Mayne J, Dewpura T, Raymon A, et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans[J]. Lipids Health Dis, 2008, 7(1):22.
9. Lagace TA, Curtis DE, Garuti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice[J]. J Clin Invest, 2006, 116(11):2995-3005.
10. Zhang DW, Lagace TA, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation[J]. J Biol Chem, 2007, 282(25):1802-1812.
11. Nassoury N, Blasiole DA, Tebon Oler A, et al. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR[J]. Traffic, 2007, 8(6):718-732.
12. Seidah NG, Awan Z, Chrétien M, et al. PCSK9: a key modulator of cardiovascular health[J]. Circ Res, 2014, 114(6):1022-1036.
13. Li J, Tumanut C, Gavigan JA, et al. Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity[J]. Biochem J, 2007, 406(2):203-207.
14. Benjannet S, Rhainds D, Essalmani R, et al. NARC-1/ PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterl[J]. J Biol Chem, 2004, 279(47):48865-48875.
15. Han B, Eacho PI, Knierman MD, et al. Isolation and Characterization of the Circulating Truncated Form of PCSK9[J]. J Lipid Res, 2014, 55(7):1505-1514.
16. Arsenault BJ, Pelletier-Beaumont E, Alméras N, et al. PCSK9 levels in abdominally obese men: association with cardiometabolic risk profile and effects of a one-year lifestyle modification proram[J]. Atherosclerosis, 2014, 236(2):321-326.
17. Baass A, Dubuc G, Tremblay M, et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents[ J]. Clin Chem, 2009, 55(9):1637-1645.
18. Brouwers MCGJ, van Greevenbroek MMJ, Konrad RJ, et al. Circulating PCSK9 is a strong determinant of plasma triacylglycerols and total cholesterol in homozygous carriers of apolipoprotein e2[J]. Clin Sci (Lond), 2014, 126(9):679-684.
19. Cariou B, Langhi C, Le Bras M, et al. Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets[J]. Natr Metab (Lond), 2013, 10(1):4.
20. Chan DC, Wong ATY, Pang J, et al. Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state[J]. Clin Sci (Lond) 2015, 128(6):379-385.
21. Chernogubova E, Strawbridge R, Mahdessian H, et al. Common and low-frequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels[J]. Arterioscler Thromb Vasc Biol, 2012, 32(6):1526-1534.
22. Kwakernaak AJ, Lambert G, Dullaart RPF. Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins[J]. Clin Biochem, 2014, 47(7-8):679-682.
23. Lakoski SG, Lagace TA, Cohen JC, et al. Genetic and metabolic determinants of plasma PCSK9 levels[J]. J Clin Endocrinol Metab, 2009, 94(7):2537-2543.
24. Mayne J, Ooi TC, Raymond A, et al. Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations[J]. Lipids Health Dis, 2013, 12(70).
25. Sullivan S, Fabbrini E, Horton JD, et al. Lack of relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people[J]. Trans Res, 2012, 158(5):302-306.
26. Kwakernaak AJ, Lambert G, Slagman MCJ, et al. Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment[J]. Atherosclerosis, 2013, 226(2):459-465.
27. Abujrad H, Mayne J, Ruzicka M, et al. Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels[J]. Atherosclerosis, 2014, 233(1):123-129.
28. Naoumova RP, Tosi I, Patel D, et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response[J]. Arterioscler Thromb Vasc Biol, 2005, 25(12):2654-2660.
29. Raal F, Panz V, Immelman A, et al. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy[J]. J Am Heart Assoc, 2013, 2(2):1-7.
30. Humphries SE, Neely RDG, Whittall RA, et al. Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9[J]. Clin Chem, 2009, 55(12):2153-2161.
31. Costet P, Cariou B, Labert G, et al. Hepatic PCSK9 expression is regulated by nutrtional status via insulin and sterol regulatory-element protein 1c[J]. J Biol Chem, 2006, 281(10):6211-6218.
32. Kapelle PJWH, Lambert G, Dullaart RPF. Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients[J]. Atherosclerosis, 2011, 214(2):432-435.
33. Awan Z, Dubuc G, Faraj M, et al. The effect of insulin on circulating PCSK9 in postmenopausal obese women[J]. Clin Biochem, 2014, 47(12):1033-1039.
34. Brouwers MCGJ, Troutt JS, van Greevenbroek MMJ, et al. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus[J]. Atherosclerosis, 2011, 217(1):263-267.
35. Mbikay M, Sirois F, Mayne J, et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities[J]. FEBS Lett, 2010, 584(4):701-706.
36. Le May C, Kourimate S, Langhi C, et al. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia[J]. Arterioscler Thromb Vasc Biol, 2009, 29(5):684-690.
37. Malloy MJ, Kane JP. Fibric Acid Derivatives (Fibrates) -Mechanism of Action[J]. In: Katzung BG, Editor. Basic and Clinical Pharmacology. 10th edition. New York:McGraw Hill Lange, 2007:569.
38. Chan DC, Hamilton SJ, Rye KA, et al. Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/ kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients[J]. Diabetes Obes Metab, 2010, 12(9):752-756.
39. Costet P, Hoffmann MM, Cariou B, et al. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients[J]. Atherosclerosis, 2010, 212(1):246-251.
40. Noguchi T, Kobayashi J, Yagi K, et al. Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study[J]. Atherosclerosis, 2011, 217(1):165-170.
41. Troutt JS, Alborn WE, Cao G, et al. Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels[J]. J Lipid Res, 2010, 51(2):345-351.
42. Sahebkar A. Circulating levels of proprotein convertase subtilisin kexin type 9 are elevated by fibrate therapy: a systematic review and meta-analysis of clinical trials[J]. Cardiol Rev. 2014: 22(6):306-312.
43. Kourimate S, Le May C, Langhi C, et al. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9[J]. J Biol Chem, 2008, 283(15):9666-9673.
44. Roubtsova A, Munkonda MN, Awan Z, et al. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue[J]. Arterioscler Thromb Vasc Bio, 2011, 31(4):785-791.
45. Mbikay M, Sirois F, Gyamera-Acheampong C, et al. Variable effects of gender and Western diet on lipid and glucose homeostasis in aged PCSK9-deficient C57BL/6 mice CSK9PC57BL/6[J]. J Diabetes, 2015, 7(1):74-84.
46. Sun XM, Eden ER, Tosi I, et al. Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia[J]. Hum Mol Genet, 2005, 14(9):1161-1169.
47. Sun H, Samarghandi A, Zhang N, et al. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor[J]. Arterioscler Thromb Vasc Biol, 2012, 32(7):1585-1595.
48. Rashid S, Curtis DE, Garuti R, et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9[J]. Proc Natl Acad Sci USA, 2005, 102(15):5374-5379.
49. Ouguerram K, Chetiveaux M, Zair Y, et al. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9[J]. Arterioscler Thromb Vasc Biol, 2004, 24(8):1448-1453.
50. Lambert G, Jarnoux AL, Pineau T, et al. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the lowdensity lipoprotein receptor[J]. Endocrinology, 2006, 14(10)7:4985-4995.
51. Tavori H, Fan D, Blakemore JL, et al. Serum proprotein convertase subtilisin/kexin type 9 and cell surface lowdensity lipoprotein receptor: evidence for a reciprocal regulation[J]. Circulation, 2013, 127(24):2403-2413.
52. Blasiole DA, Oler AT, Attie AD. Regulation of ApoB secretion by the low density lipoprotein receptor requires exit from the endoplasmic reticulum and interaction with ApoE or ApoB[J]. J Biol Chem, 2008, 283(17):11374-11381.
53. Levy E, Ben Djoudi Ouadda A, Spahis S, et al. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells[J]. Atherosclerosis, 2013, 227(2):297-306.
54. Rashid S, Tavori H, Brown PE, et al. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms[J]. Circulation, 2014, 130(5):431-441.
55. Poirier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2[J]. J Biol Chem, 2008, 283(4):2363-2372.
56. Canuel M, Sun X, Asselin MC, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)[J]. PLoS One, 2013, 8(5):e64145.
57. Frykman PK, Brown MS, Yamamoto T, et al. Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor[J]. Proc Natl Acad Sci USA, 1995, 92(18):8453-8457.
58. Demers A, Lauzier B, Des Rosiers C, et al. Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Targets the CD36 Receptor for Degradation[J]. Arterioscler Thromb Vasc Biol. 2013, 33(5):A77.
59. Masuda D, Hirano K, Oku H, et al. Chylomicron remnants are increased in the postprandial state in CD36 deficiency[J]. J Lipid Res, 2009, 50(5):999-1011.
60. Ooi TC, Ooi DS. The atherogenic significance of an elevated plasma triglyceride level[J]. Crit Rev Clin Lab Sci, 1998, 35(6):489-516.
61. Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels[J]. J Am Coll Cardiol, 2012, 60(19):1888-1898.
62. Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACETIMI 57): a randomised, placebo-controlled, dose-ranging, phase-2 study[J]. Lancet, 2007, 380(9858):2007-2017.
63. Hirayama A, Honarpour N, Yoshida M, et al. Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular Risk[J]. Circ J, 2014, 78(5):1073-1082.
64. Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 Monotherapy for Hypercholesterolemia Clinical Trial of Evolocumab[J]. J Am Coll Cardiol, 2014, 63(23):2531-2540.
65. Mckenney JM, Harm PD, Korem MJ, et al. Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy[J]. J Am Coll Cardiol, 2012, 59(25):2344-2353.
66. Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The LAPLACE-2 Randomized Clinical Trial[J]. JAMA, 2014, 311(18):1870-1882.
67. Roth EM, Taskinen M, Ginsberg HN, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week double-blind, randomized Phase 3 trial[J]. Int J Cardiol, 2014, 176(1):55-61.
68. Sullivan D, Olsson AG, Scott R, et al. Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol[J]. JAMA. 2014: 308(23); 2497-2506.
69. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebocontrolled trial of evolocumab in hyperlipidemia[J]. N Engl J Med, 2014, 370(19):1809-1819.
70. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial[J]. Lancet, 2012, 380(9836):29-36.
71. Raal F, Scott R, Somaratne R, et al. Low-Density Lipoprotein Cholesterol - Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia[J]. Circulation, 2012, 126(20):2408-2417.
72. Stein EA, Honarpour N, Wasserman SM, et al. Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia[J]. Circulation, 2013, 128(19):2113-2120.
73. Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2015, 385(9965):341-350.
74. Raal FJ, Stein EA, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebocontrolled trial[J]. Lancet, 2015, 385(9965):331-340.
75. Stein EA, Giugliano RP, Koren MJ, et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies?: pooled analysis of 1359 patients in four phase 2 trials[J]. Eur Heart J, 2014, 35(33):2249-2259.